Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment - extension of further conditions for nintedanib (Ofev®)
2020	National Institute for Health and Care Excellence (NICE)	Ustekinumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 633
2020	NIHR Health Technology Assessment programme	Stratified Care for Patients with Sciatica and Suspected Sciatica in Primary Care: a randomised trial (the SCOPiC trial - SCiatica Outcomes in Primary Care)
2020	NIHR Health Technology Assessment programme	Medically unexplained symptoms(MUS): primary care intervention
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Effectiveness of Music Therapy for Autism Spectrum Disorder, Dementia, Depression, Insomnia and Schizophrenia
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice polatuzumab vedotin (Polivy®) in combination with bendamustine and rituximab (Pola-BR) for the treatment of r/r DLBCL
2020	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 634
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of tafamidis (Vyndaqel®) for the treatment of wild-type or hereditary transthyretin amyloidosis
2020	Agency for Healthcare Research and Quality (AHRQ)	Therapies for clinically localized prostate cancer
2020	National Institute for Health and Care Excellence (NICE)	Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 635
2020	NIHR Health Technology Assessment programme	A randomised parallel group double blind placebo-controlled dose ranging Trial of low dose adjunctive alTeplase during priMary PCI (T-TIME)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice on a potential candidate for conditional inclusion of ataluren (Translarna®) for Duchenne's muscular dystrophy
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating refractory myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 636
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: iStent® and iStent inject® trabecular bypass for micro-invasive glaucoma surgery (MIGS)]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS advice concerning siponimod (Mayzent®) for the treatment of secondary progressive multiple sclerosis
2020	National Institute for Health and Care Excellence (NICE)	Ranibizumab for treating diabetic retinopathy (terminated appraisal). NICE technology appraisal guidance 637
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice venetoclax (Venclyxto®) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 638
2020	NIHR Health Technology Assessment programme	Pre-Operative Behavioural Intervention to Reduce Drinking before elective orthopaedic Surgery (Pre-Op BIRDS)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: prevention of cardiovascular events and safety of SGLT2 inhibitors compared to DPP-4 inhibitors in a real-world setting in patients with type 2 diabetes]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of glucagon nasal powder (Baqsimi®) for the treatment of severe hypoglycaemia
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020	National Institute for Health and Care Excellence (NICE)	Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. NICE technology appraisal guidance 639
2020	NIHR Health Technology Assessment programme	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020	NIHR Health Technology Assessment programme	Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Adverse effects of messenger RNA vaccines
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders, wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatment of depression in children and adolescents
2020	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant. NICE technology appraisal guidance 640
2020	National Institute for Health and Care Excellence (NICE)	Testing strategies for Lynch syndrome in people with endometrial cancer. NICE diagnostics guidance 42
2020	NIHR Health Services and Delivery Research programme	Identifying appropriate symbol communication aids for children who are non-speaking: enhancing clinical decision making
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: evolving portrait of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) in Québec, an evaluation in the real-world context of care, 2013 to 2018]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Alpha-1-antitrypsin genotyping
2020	National Institute for Health and Care Excellence (NICE)	Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma. NICE technology appraisal guidance 641
2020	National Institute for Health and Care Excellence (NICE)	Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke. NICE diagnostics guidance 41
2020	NIHR Health Technology Assessment programme	Surgical fixation compared with cast immobilisation for adults with a bicortical fracture of the scaphoid waist: the SWIFFT RCT
2020	NIHR Health Technology Assessment programme	What is the effectiveness of varenicline compared with nicotine replacement therapy for long term smoking cessation and clinically important outcomes such as mortality, myocardial infarction and frequency of service use? Evidence from the Clinical Practice Research Datalink
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: RebinynTM (nonacog beta pegol) – coagulation factor IX (recombinant), notice of inclusion on the Liste des produits du système du sang du Québec]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Point of care vascular ultrasound
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	PSMA PET/CT imaging for informing treatment of patients with prostate cancer
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatments for acute pain: a systematic review
2020	National Institute for Health and Care Excellence (NICE)	Gilteritinib for treating relapsed or refractory acute myeloid leukaemia. NICE technology appraisal guidance 642
2020	National Institute for Health and Care Excellence (NICE)	High-sensitivity troponin tests for the early rule out of NSTEMI. NICE diagnostics guidance 40
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: recommendations concerning the information required to monitor nusinersen use in real-world settings]
2020	Penn Medicine Center for Evidence-based Practice (CEP)	Early mobilization to reduce medical inpatient length of stay and adverse
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Arthroscopic injection of a bioadhesive hydrogel implant (JointRep), in conjunction with microfracture, for treatment of osteochondral defects of the knee
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 643
2020	National Institute for Health and Care Excellence (NICE)	Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test). NICE diagnostics guidance 39
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Review of immunoglobulin use for primary immunodeficiency diseases with antibody deficiency
2020	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating NTRK fusion-positive solid tumours. NICE technology appraisal guidance 644
2020	NIHR Health Services and Delivery Research programme	Identifying nurse-staffing requirements using the Safer Nursing Care Tool. Modelling the costs and consequences of real world application to address variation in patient need on hospital wards
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Atectura® Breezhaler® (indacaterol acetate/mometasone furoate)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020	National Institute for Health and Care Excellence (NICE)	Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 645
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Advice reassessment osimertinib (Tagrisso®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Burosumab (new therapeutic indication: X-linked hypophosphataemia, ≥ 18 years)]
2020	National Institute for Health and Care Excellence (NICE)	Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal). NICE technology appraisal guidance 646
2020	NIHR Health Technology Assessment programme	Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020	NIHR Public Health Research (PHR) programme	Feasibility study of how best to engage obese men in narrative SMS (short message system) and incentive interventions for weight loss, to inform a future effectiveness and cost-effectiveness trial
2020	NIHR Health Technology Assessment programme	Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Avelumab in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Dravet-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal). NICE technology appraisal guidance 647
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cannabidiol - reassessment after expiry of the deadline (Lennox-Gastaut-Syndrome, ≥ 2 years, combination with clobazam)]
2020	National Institute for Health and Care Excellence (NICE)	Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 648
2020	National Institute for Health and Care Excellence (NICE)	Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 649
2020	NIHR Public Health Research (PHR) programme	Healthy Dads, Healthy Kids UK: a cultural adaptation and feasibility study of a weight management programme for fathers of younger children
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
2020	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 650
2020	NIHR Health Services and Delivery Research programme	An evaluation of alcohol treatment centres: implications for service delivery, patient benefit and harm reduction
2020	Swiss Federal Office of Public Health (FOPH)	Glinides and glitazones in the treatment of type 2 diabetes
2020	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of the macrobiotic diet]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020	National Institute for Health and Care Excellence (NICE)	Naldemedine for treating opioid-induced constipation. NICE technology appraisal guidance 651
2020	NIHR Health Technology Assessment programme	Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 653
2020	NIHR Health Technology Assessment programme	Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2020	National Institute for Health and Care Excellence (NICE)	Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. NICE technology appraisal guidance 654
2020	NIHR Health Services and Delivery Research programme	Understanding how frontline staff use patient experience data for service improvement - an exploratory case study evaluation and national survey (US-PEx)
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea]
2020	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Amnion membrane for topical treatment of ophthalmic disorders (caused by disease and/or trauma), and wound dressings for skin burns and ulcers on the craniofacial area, torso, and limbs
2020	National Institute for Health and Care Excellence (NICE)	Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 655
2020	NIHR Health Services and Delivery Research programme	Young people with Attention Deficit Hyperactivity Disorder (ADHD) in transition from children's services to adult services (Catch-uS): a mixed methods project using national surveillance, qualitative and mapping studies
2020	Norwegian Institute of Public Health (NIPH)	[Hyperbaric oxygen therapy for radiation-induced cystitis]
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	GVS assessment of oral semaglutide (Rybelsus®)
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Gilteritinib (Relapsed or Refractory Acute Myeloid Leukaemia with an FLT3 Mutation)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sleep position therapy for obstructive sleep apnoea - Addendum to commission E20-07]
2020	National Institute for Health and Care Excellence (NICE)	Siponimod for treating secondary progressive multiple sclerosis. NICE technology appraisal guidance 656
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
2020	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]